PTC Therapeutics (PTCT) Projected to Release Quarterly Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is anticipated to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect PTC Therapeutics to announce earnings of $0.2071 per share and revenue of $304.60 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.68. The business had revenue of $360.52 million for the quarter, compared to analyst estimates of $298.63 million. The business’s revenue for the quarter was up 101.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.83) EPS. On average, analysts expect PTC Therapeutics to post $1.19 EPS for the current fiscal year and $1.90 EPS for the next fiscal year.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $62.62 on Thursday. The stock has a 50 day simple moving average of $66.73 and a 200-day simple moving average of $71.65. PTC Therapeutics has a 12-month low of $58.80 and a 12-month high of $90.87.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. UBS Group restated a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of PTC Therapeutics in a research note on Thursday, October 15th. Weiss Ratings upgraded PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Truist Financial started coverage on PTC Therapeutics in a report on Friday, October 16th. They issued a “hold” rating and a $62.00 target price for the company. Cantor Fitzgerald raised their target price on PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a report on Tuesday, September 22nd. Finally, Morgan Stanley boosted their target price on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $94.93.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, Director Michael Schmertzler sold 12,500 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $72.94, for a total value of $911,750.00. Following the completion of the transaction, the director directly owned 1,349,094 shares of the company’s stock, valued at approximately $98,402,916.36. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the sale, the director owned 22,500 shares of the company’s stock, valued at approximately $1,466,100. The trade was a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 77,370 shares of company stock valued at $5,322,261. 5.30% of the stock is currently owned by corporate insiders.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.